Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam Pharmaceuticals has a market capitalization of $57.78 billion.

President Donald Trump threatened 100% tariffs on some drug imports.

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with

Reddit, Wingstop, and Generac led large-cap gains last week on strong Q2 results and upbeat guidance across multiple sectors.

Alnylam sees strong Amvuttra uptake in ATTR-CM with $150 million revenue boost; analysts hike price targets following FDA approval and launch momentum.

Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across the TTR and Rare franchises.

Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics.